1 Min Read
May 18 (Reuters) - PHARMA MAR SA:
* AFTER POSITIVE RESULTS OBTAINED IN ENDOMETRIAL CANCER WITH LURBINECTEDIN PLANS TO INITIATE PIVOTAL PHASE III STUDY Source text: bit.ly/2rudx52
Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.